**Definition**

Signifor® LAR is an injectable cyclohexapeptide somatostatin analog. Pasireotide exerts its pharmacological activity via binding to somatostatin receptors (SSTRs). There are five known human somatostatin receptor subtypes: SSTR 1, 2, 3, 4, and 5. These receptor subtypes are expressed in different tissues under normal physiological conditions. Somatostatin analogs bind to SSTRs with different potencies. Pasireotide binds with high affinity to four of the five SSTRs.

**Dosing and Administration**

[Signifor LAR Package Insert]

**Related Medical Guideline**

[Off-Label Use of FDA-Approved Drugs and Biologicals]

**Guideline**

Pasireotide (Signifor LAR) is considered medically necessary for acromegaly when all of the following criteria are met:

1. Inadequate response to surgery and/or surgery is not an option
2. Previous failed trial or contraindication to a somatostatin analogue (e.g., octreotide [Sandostatin® LAR, Lanreotide [Somatuline® Depot]) and a dopamine agonist (e.g., bromocriptine, cabergoline)
3. Signifor LAR is prescribed/recommended by an endocrinologist

**Limitations/Exclusions**

Pasireotide (Signifor LAR) is not considered medically necessary for conditions other than acromegaly and when the criteria above are not met.
Applicable Procedure Codes

| J2502 | Injection, pasireotide long acting, 1 mg |

Applicable Diagnosis Codes

| E22.0 | Acromegaly and pituitary gigantism |

References

Specialty-matched clinical peer review.